Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.

A Awada; S Ochsenreither; RL Eefsen; D Arnold; J Yachnin; P Pfeiffer; C Jungels; Richard Greil; L Poulsen; E Van Cutsem; L Thorsson; C Svedman; I Garcia-Ribas; J Collignon

doi:10.1200/JCO.2021.39.15_suppl.e16228

Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.

A Awada, S Ochsenreither, RL Eefsen, D Arnold, J Yachnin, P Pfeiffer, C Jungels, Richard Greil, L Poulsen, E Van Cutsem, L Thorsson, C Svedman, I Garcia-Ribas, J Collignon

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

2 Citations (Web of Science)

Original language	English
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	39
Issue number	15
DOIs	https://doi.org/10.1200/JCO.2021.39.15_suppl.e16228
Publication status	Published - 2021

Access to Document

10.1200/JCO.2021.39.15_suppl.e16228

Cite this

Awada, A., Ochsenreither, S., Eefsen, RL., Arnold, D., Yachnin, J., Pfeiffer, P., Jungels, C., Greil, R., Poulsen, L., Van Cutsem, E., Thorsson, L., Svedman, C., Garcia-Ribas, I., & Collignon, J. (2021). Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer. JOURNAL OF CLINICAL ONCOLOGY , 39(15). https://doi.org/10.1200/JCO.2021.39.15_suppl.e16228

Awada, A ; Ochsenreither, S ; Eefsen, RL et al. / Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer. In: JOURNAL OF CLINICAL ONCOLOGY 2021 ; Vol. 39, No. 15.

@article{1801bca640214918bcbd7716514fb42b,

title = "Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.",

author = "A Awada and S Ochsenreither and RL Eefsen and D Arnold and J Yachnin and P Pfeiffer and C Jungels and Richard Greil and L Poulsen and {Van Cutsem}, E and L Thorsson and C Svedman and I Garcia-Ribas and J Collignon",

year = "2021",

doi = "10.1200/JCO.2021.39.15_suppl.e16228",

language = "English",

volume = "39",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "15",

}

Awada, A, Ochsenreither, S, Eefsen, RL, Arnold, D, Yachnin, J, Pfeiffer, P, Jungels, C, Greil, R, Poulsen, L, Van Cutsem, E, Thorsson, L, Svedman, C, Garcia-Ribas, I & Collignon, J 2021, 'Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.', JOURNAL OF CLINICAL ONCOLOGY , vol. 39, no. 15. https://doi.org/10.1200/JCO.2021.39.15_suppl.e16228

Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer. / Awada, A; Ochsenreither, S; Eefsen, RL et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 39, No. 15, 2021.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.

AU - Awada, A

AU - Ochsenreither, S

AU - Eefsen, RL

AU - Arnold, D

AU - Yachnin, J

AU - Pfeiffer, P

AU - Jungels, C

AU - Greil, Richard

AU - Poulsen, L

AU - Van Cutsem, E

AU - Thorsson, L

AU - Svedman, C

AU - Garcia-Ribas, I

AU - Collignon, J

PY - 2021

Y1 - 2021

U2 - 10.1200/JCO.2021.39.15_suppl.e16228

DO - 10.1200/JCO.2021.39.15_suppl.e16228

M3 - Abstract (Journal)

SN - 0732-183X

VL - 39

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 15

ER -

Awada A, Ochsenreither S, Eefsen RL, Arnold D, Yachnin J, Pfeiffer P et al. Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer. JOURNAL OF CLINICAL ONCOLOGY . 2021;39(15). doi: 10.1200/JCO.2021.39.15_suppl.e16228